临时下肢制动患者药物血栓预防的系统综述与网络Meta分析
该网络Meta分析纳入13项随机试验共6857例因损伤行临时下肢制动的患者,比较不同药物血栓预防与无预防的效果。结果显示,与无治疗相比,低分子肝素(LMWH)降低任何静脉血栓栓塞(VTE)、临床检出深静脉血栓(DVT)和肺栓塞(PE)风险,磺达肝癸钠降低任何VTE和临床检出DVT风险,对PE结果不确定。未发现除药物种类外的效应修饰因素。
要点
- LMWH较无预防降低任何VTE(OR 0.52)、临床DVT(OR 0.39)和PE(OR 0.16)风险。
- 磺达肝癸钠较无预防降低任何VTE(OR 0.13)和临床DVT(OR 0.10),PE结果不确定。
- 未发现除预防药物种类外的治疗效应修饰因素。
核心结论
- 磺达肝癸钠或LMWH药物血栓预防似可降低临时下肢制动患者无症状及临床检出VTE的比值。
- 治疗效果因结局而异,且并非总是确定。
- 除所用血栓预防药物外,未能识别其他治疗效应修饰因素。
研究设计与样本
- 系统综述与网络Meta分析,纳入报告VTE或出血结局的随机试验。
- 比较血栓预防药物之间或与无药物预防,共纳入13项随机试验、6857例参与者。
- 对每个结局或药物进行网络Meta分析,并采用研究水平网络Meta回归探索人群特征、损伤类型、损伤治疗或预防时长与治疗效应的关联。
主要发现
- 与无治疗相比,LMWH降低任何VTE风险(OR 0.52;95% CrI 0.37-0.71)。
- 与无治疗相比,LMWH降低临床检出DVT风险(OR 0.39;95% CrI 0.12-0.94)。
- 与无治疗相比,LMWH降低PE风险(OR 0.16;95% CrI 0.01-0.74)。
- 与无治疗相比,磺达肝癸钠降低任何VTE风险(OR 0.13;95% CrI 0.05-0.30)。
- 与无治疗相比,磺达肝癸钠降低临床检出DVT风险(OR 0.10;95% CrI 0.01-0.86),对PE结果不确定(OR 0.40;95% CrI 0.01-7.53)。
关键数值与推荐
- 任何VTE:LMWH vs 无治疗 OR 0.52(95% CrI 0.37-0.71);磺达肝癸钠 vs 无治疗 OR 0.13(95% CrI 0.05-0.30)。
- 临床检出DVT:LMWH vs 无治疗 OR 0.39(95% CrI 0.12-0.94);磺达肝癸钠 vs 无治疗 OR 0.10(95% CrI 0.01-0.86)。
- PE:LMWH vs 无治疗 OR 0.16(95% CrI 0.01-0.74);磺达肝癸钠 vs 无治疗 OR 0.40(95% CrI 0.01-7.53)。
临床怎么用
- 对因损伤行临时下肢制动的患者,可考虑使用LMWH或磺达肝癸钠进行药物血栓预防以降低VTE风险。
- 选择药物时需注意不同结局的效应差异,磺达肝癸钠对PE的效应尚不确定。
- 治疗效应可能因结局而异,临床决策应结合个体情况。
局限性
- 治疗效应并非对所有结局均确定,部分结果置信区间宽。
- 除药物种类外未识别其他效应修饰因素,可能限制个体化应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thromboprophylaxis has the potential to reduce venous thromboembolism (VTE) following lower limb immobilization resulting from injury. OBJECTIVES: We aimed to estimate the effectiveness of thromboprophylaxis, compare different agents, and identify any factors associated with effectiveness. METHODS: We undertook a systematic review and network meta-analysis (NMA) of randomized trials reporting VTE or bleeding outcomes that compared thromboprophylactic agents with each other or to no pharmacological prophylaxis, for this indication. An NMA was undertaken for each outcome or agent used, and a series of study-level network meta-regressions examined whether population characteristics, type of injury, treatment of injury, or duration of thromboprophylaxis were associated with treatment effect. RESULTS: Data from 6857 participants across 13 randomized trials showed that, compared with no treatment, low molecular weight heparin (LMWH) reduced the risk of any VTE (odds ratio [OR]: 0.52; 95% credible interval [CrI]: 0.37-0.71), clinically detected deep vein thrombosis (DVT) (OR: 0.39; 95% CrI: 0.12-0.94) and pulmonary embolism (PE) (OR: 0.16; 95% CrI: 0.01-0.74), whereas fondaparinux reduced the risk of any VTE (OR: 0.13; 95% CrI: 0.05-0.30) and clinically detected DVT (OR: 0.10; 95% CrI: 0.01-0.86), with inconclusive results for PE (OR: 0.40; 95% CrI: 0.01-7.53). CONCLUSIONS: Thromboprophylaxis with either fondaparinux or LMWH appears to reduce the odds of both asymptomatic and clinically detected VTE in people with temporary lower limb immobilization following an injury. Treatment effects vary by outcome and are not always conclusive. We were unable to identify any treatment effect modifiers other than thromboprophylactic agent used.
引用
- Horner D, Stevens JW, Pandor A, et al. Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta-analysis. J Thromb Haemost. 2019. PMID: 31654551. doi:10.1111/jth.14666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。